MapLight Therapeutics, Inc. MPLT Operating lease liabilities

Operating lease liabilities at other companies

LBR

LB Pharmaceuticals Inc Common StockLBRX

——

Xenon PharmaceuticalsXENE

——

Zevra Therapeutics, Inc.ZVRA

——

Catalyst PharmaceuticalCPRX

——

Praxis Precision Medicines, Inc.PRAX

——

Maze Therapeutics, Inc. Common StockMAZE

——

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B+109%

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's operating lease liabilities?: MapLight Therapeutics, Inc. (MPLT) reported operating lease liabilities of -$211K in Q1 2026.